膀胱腫瘍の再発防止に関する研究 --フトラフール内服による再発防止効果--

Abstract

Adverse reactions due to Futraful administration were subjectively observed in 9 of 75 cases (12%): 4 cases with skin eruption, 2 cases with anorexia, and 3 cases with gastrointestinal disorders. Laboratory examination of 35 cases, after one-year administration of Futraful, showed the abnormal findings in 9 cases (23.7%): 3 cases with decreased blood cell count, 3 cases with elevated GOT and GPT, and 3 cases with elevated alkaline phosphatase level. A problem in bladder cancer after a conservative is the frequent local recurrence of the tumor. Intravesical administration of MMC or Thio-TEPA and/or oral administration of SLA have been recognized as a successful prophylactic measure. In this paper, the prophylactic effect of Futraful administration was tested between 75 patients and 110 controls with transitional cell carcinoma. Futraful was orally administered 600-800mg a day for one to two years to the patients operated by either TUR (TUC), simple resection, or partial cystectomy. The rate of recurrence was significantly lower for the postoperative period of 0-10 months and lower, though insignificantly, for that of 11-24 months in the patients operated for the first time, as compared to that in the controls; the rate of postoperative recurrence after 12 months being 15.5% in the patients treated by Futraful and 25.5% in the controls. In the recurrent cases, however, administration of Futraful effectively reduced the recurrence only for the postoperative period of 0-6 months; the rate of recurrence being higher thereafter in the patients treated by Futraful than in the controls.